OTC · BRRGF
BerGenBio ASA
$97.09$0.00 (0.0%)
BerGenBio ASA’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · TRYPF · USD
Stock price, earnings
Quote as of May 1, 2024, 07:17 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Tryp Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 38.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Tryp Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Tryp Therapeutics Inc. is a biopharmaceutical company dedicated to identifying and advancing novel therapeutic compounds for medical conditions characterized by significant unmet needs. Its flagship development initiative, known as PFN, focuses on addressing neuropsychiatric disorders by utilizing precisely formulated synthetic psilocybin. Within the PFN framework, specific drug candidates TRP-8802 and TRP-8803 are being developed to potentially treat a range of complex conditions, including fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. To support its research and clinical endeavors, the company collaborates with Calvert Labs for the conceptualization and execution of exploratory studies related to its psilocybin-based neuropsychiatric program. Additionally, a partnership with Fluence provides essential guidance and instruction for the psychotherapeutic components of Tryp's clinical trials. Established in 2019, the organization initially operated as Artos Pharma Corp. before rebranding as Tryp Therapeutics Inc. in June 2020. Its operations are headquartered in Kelowna, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$97.09$0.00 (0.0%)
BerGenBio ASA’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.10$0.00 (0.0%)
Deltex Medical Group plc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$1.99+$0.01 (+0.3%)
Polydex Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 1.19% below the high.
$0.02+$0.00 (+4.79%)
VIVO Cannabis Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.5% below the high.
$0.27$0.00 (0.0%)
Qualis Innovations, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.77% below the high.
$0.02+$0.00 (+12.43%)
Rhinomed Limited’s quoted price sits in the lower half of its reported 52-week range, 72.78% below the high.
$0.12-$0.10 (-44.37%)
Fire & Flower Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 31.43% below the high.
$0.11$0.00 (0.0%)
Bloom Health Partners Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.89% below the high.
